

04-11-07

IFW

Express Mail No. EV 922 264 936 US



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Collins *et al.*

Confirmation No.: 4775

Serial No.: 10/654,112

Art Unit: 1626

Filed: September 2, 2003

Examiner: Ebenezer O. Sackey

For: MODULATION OF CCR4  
FUNCTION

Attorney Docket No.: 11134-065-999

**TRANSMITTAL**

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed herewith are a Statement Under 37 C.F.R. 3.73(b), Revocation of Previous Power of Attorney and New Power of Attorney By Assignee, and assignment documents for Assignee AMGEN, Inc.; Revocation and Power of Attorney, Statement Under 37 C.F.R. 3.73(b), and assignment to Assignee, ChemoCentryx, Inc., submitted in connection with the above-identified patent application. No fee is believed to be due for this paper. However, the Commissioner is hereby authorized to charge any required fee to Jones Day Deposit Account No. 50-3013 (order no. 893053-999065)

Respectfully submitted,

Date: April 9, 2007

  
Roger C. Rich

For: Anthony M. Insogna (Reg. No. 35,203)

54,398

(Reg. No.)

**JONES DAY**

222 East 41st Street  
New York, New York 10017  
(212) 326-3939



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Collins *et al.*

Docket No.: 11134-065-999

Serial No. 10/654,112

Group Art Unit: 1626

Filed: September 2, 2003

Examiner: Ebenezer O. Sackey

For: MODULATION OF CCR4 FUNCTION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT UNDER 37 C.F.R. 3.73(b)**

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application, which is a divisional of U.S. Application No. 09/975,566 filed October 11, 2001. A chain of title from the inventors of the above-identified application to Amgen Inc. is shown below.

1. From inventors Tassie Collins, Hossen Mahmud, Julio Medina, Feng Xu, and Xuemei Wang To: Tularik, Inc. the assignment recorded November 25, 2002, in the USPTO at Reel 013520, Frame 0300.
2. From Tularik, Inc. To: Arrow Acquisition, LLC the merger recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0003.
3. From Arrow Acquisition, LLC To: Amgen SF, LLC the change in name recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0812.
4. From Amgen SF, LLC To: Amgen Inc. the assignment a copy of which is attached herewith.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

**REVOCATION OR PREVIOUS POWER OF ATTORNEY AND**  
**NEW POWER OF ATTORNEY BY ASSIGNEE**

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **20583** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

**REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS**

Please send all future correspondence and direct telephone calls to Customer Number **20583**.

Respectfully submitted,

Date November 27, 2006

By: Stuart L. Watt  
Stuart L. Watt  
Vice President, Law  
AMGEN Inc.

**ASSIGNMENT OF PATENT APPLICATION**

**JOINT**

WHEREAS, Tassie Collins of 247 W. 40th Avenue, San Mateo, CA 94403; Hossen Mahmud of 384 Treeline Park, #2125, San Antonio, TX 78209; Julio C. Medina of 1407 Cedar Street, San Carlos, CA 94070; Feng Xu of 2129 Edgewood Drive, Palo Alto, CA 94303; Xuemei Wang of 2153 Vista Del Mar, San Mateo, CA 94404; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention:           **MODULATION OF CCR4 FUNCTION**

Date(s) of execution of Declaration: 01/11/02; 03/02/02; 01/11/02; 02/23/02; and  
01/14/02

Filing Date:                October 11, 2001

Application No.:           09/975,566

WHEREAS, Tularik Inc., a corporation of United States, located at Two Corporate Drive, South San Francisco, CA, 94080, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: Aug. 15, 2002

Tassie Collins  
Tassie Collins

SIGNATURE WITNESSED BY:

(1) Dated: 8.15.02

Donna J. Gursler

(2) Dated: 8/15/02

C. J. P. Q.

Dated: \_\_\_\_\_

Hossen Mahmud  
Hossen Mahmud

SIGNATURE WITNESSED BY:

(1) Dated: 8-22-

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: 8-22-02

Julio C. Medina  
Julio C. Medina

SIGNATURE WITNESSED BY:

(1) Dated: 8-22-02

[Signature]

(2) Dated: 8-22-02

[Signature]

Dated: \_\_\_\_\_

Feng Xu  
Feng Xu

SIGNATURE WITNESSED BY:

(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: \_\_\_\_\_

\_\_\_\_\_  
Tassie Collins

SIGNATURE WITNESSED BY:

(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_


\_\_\_\_\_

Dated: 08/25/02

  
\_\_\_\_\_  
Hossen Mahmud

SIGNATURE WITNESSED BY:

(1) Dated: 08/25/02

  
\_\_\_\_\_

(2) Dated: 08/25/02

Armina Mahmud  
\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_  
Julio C. Medina

SIGNATURE WITNESSED BY:

(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_  
Feng Xu

SIGNATURE WITNESSED BY:

(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: \_\_\_\_\_

\_\_\_\_\_  
Tassie Collins

SIGNATURE WITNESSED BY:

(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_  
Hossen Mahmud

SIGNATURE WITNESSED BY:

(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: \_\_\_\_\_

\_\_\_\_\_  
Julio C. Medina

SIGNATURE WITNESSED BY:


(1) Dated: \_\_\_\_\_

\_\_\_\_\_

(2) Dated: \_\_\_\_\_

\_\_\_\_\_

Dated: 08/22/02

  
\_\_\_\_\_  
Feng Xu

SIGNATURE WITNESSED BY:

(1) Dated: 08/22/02

Ushadilip

(2) Dated: 08/22/02


T. Xu

Assignment

Attorney Docket No.: 018781-008600US


Page 3

Dated. / 8/20/02


  
Xuemei Wang

SIGNATURE WITNESSED BY:

(1) Dated: 8/20/02



(2) Dated: 8/21/02



WC 9043996 v1



# Delaware

PAGE 1

*The First State*


I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"TULARIK INC.", A DELAWARE CORPORATION,

WITH AND INTO "ARROW ACQUISITION, LLC" UNDER THE NAME OF "ARROW ACQUISITION, LLC", A LIMITED LIABILITY COMPANY ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE THIRTEENTH DAY OF AUGUST, A.D. 2004, AT 10:34 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE THIRTEENTH DAY OF AUGUST, A.D. 2004, AT 5 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COUNTY RECORDER OF DEEDS.



*Harriet Smith Windsor*

Harriet Smith Windsor, Secretary of State

3780036 8100M

040593536

AUTHENTICATION: 3293954

DATE: 08-13-04

State of Delaware  
Secretary of State  
Division of Corporations  
Delivered 10:34 AM 08/13/2004  
FILED 10:34 AM 08/13/2004  
SRV 040593536 - 3780036 FILE

**CERTIFICATE OF MERGER  
OF  
TULARIK INC.  
WITH AND INTO  
ARROW ACQUISITION, LLC**

Pursuant to Title 8, Section 264(c) of the Delaware General Corporation Law and Title 6, Section 18-209 of the Limited Liability Company Act, the undersigned limited liability company formed and existing under and by virtue of the Delaware Limited Liability Company Act does hereby certify:

1. The constituent business entities participating in the merger herein certified are:
  - (i) Tularik Inc., a Delaware corporation; and
  - (ii) Arrow Acquisition, LLC, a Delaware limited liability company.
2. The Agreement and Plan of Merger (the "Agreement and Plan of Merger"), dated as of March 28, 2004, by and among Amgen Inc., a Delaware corporation, Arrow Acquisition, LLC and Tularik Inc., has been approved, adopted, certified, executed, and acknowledged by each of the aforesaid constituent entities in accordance with the provisions of subsection (b) of Section 18-209 of the Delaware Limited Liability Company Act and in accordance with the provisions of subsection (c) of Section 264 of the General Corporation Law of the State of Delaware.
3. The name of the surviving limited liability company in the merger herein certified is Arrow Acquisition, LLC.
4. The Certificate of Formation of Arrow Acquisition, LLC, a Delaware limited liability company, as filed with the Secretary of State of Delaware on March 22, 2004, and as now in force and effect, shall continue to be the Certificate of Formation of said surviving limited liability company until amended and changed pursuant to the provisions of the Delaware Limited Liability Company Act.
5. The executed Agreement and Plan of Merger is on file at the principal place of business of the aforesaid surviving limited liability company, the address of which is as follows: One Amgen Center Drive, Thousand Oaks, California 91320-1799.
6. ~~A copy of the aforesaid Agreement and Plan of Merger will be furnished by the~~ aforesaid surviving limited liability company, on request, and without cost, to any stockholder of the constituent Delaware corporation or any member of the constituent surviving limited liability company.
7. The effective time and date of the merger shall be 5:00 p.m. (Eastern Time) on August 13, 2004.

IN WITNESS WHEREOF, said limited liability company has caused this certificate to be signed by an authorized person, this 13th day of August, 2004.

ARROW ACQUISITION, LLC,  
a Delaware limited liability company

By: 

Name: David J. Scott. P  
Vice President and Secretary


# Delaware

PAGE 1

*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF "ARROW ACQUISITION, LLC", CHANGING ITS NAME FROM "ARROW ACQUISITION, LLC" TO "AMGEN SF, LLC", FILED IN THIS OFFICE ON THE THIRTEENTH DAY OF AUGUST, A.D. 2004, AT 11:11 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID RESTATED CERTIFICATE IS THE THIRTEENTH DAY OF AUGUST, A.D. 2004, AT 5:01 O'CLOCK P.M.



3780036 8100

040593762

*Harriet Smith Windsor*

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 3294065

DATE: 08-13-04

**AMENDED AND RESTATED CERTIFICATE OF FORMATION  
OF  
ARROW ACQUISITION, LLC**

**August 13, 2004**

1. This Amended and Restated Certificate of Formation of Arrow Acquisition, LLC is being duly executed and filed by David J. Scott, as an authorized person, pursuant to Section 18-208 of the Delaware Limited Liability Company Act, to amend and restate the Certificate of Formation of Arrow Acquisition, LLC originally filed on March 22, 2004.

2. The Certificate of Formation of the limited liability company is hereby amended and restated in its entirety to read as follows:

"FIRST. The name of the limited liability company is Amgen SF, LLC.

SECOND. The address of the registered office and the name and the address of the registered agent of the limited liability company required to be maintained by Section 18-104 of the Delaware Limited Liability Company Act are National Registered Agents, Inc., 9 East Loockerman Street, Suite 1B, Dover, Kent County, Delaware 19901."

3. The effective date and time of this Amended and Restated Certificate of Formation shall be August 13, 2004 at 5:01 p.m. Eastern Time.

[Signature Page Follows]

OC684843.1

State of Delaware  
Secretary of State  
Division of Corporations  
Delivered 11:11 AM 08/13/2004  
FILED 11:11 AM 08/13/2004  
SRV 040593762 - 3780036 FILE

IN WITNESS WHEREOF, the undersigned has executed this Amended and Restated  
Certificate of Formation as of the date first above written.



David J. Scott  
Authorized Person

11

ASSIGNMENT

WHEREAS, AMGEN SF, LLC (hereinafter "ASF"), a limited liability company incorporated under the laws of the State of Delaware, United States of America, and having a place of business at 1120 Veterans Boulevard, South San Francisco, California 94080, is the assignee of interest of the inventions set forth in U.S. and foreign patents and U.S. and foreign Patent Applications, listed on Appendix A hereto;

WHEREAS, AMGEN INC. (hereinafter "AMGEN"), a corporation organized under the laws of the State of Delaware, United States of America, and having a place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, is desirous of acquiring all interest in and to said inventions and to the Patents and Patent Applications listed in Appendix A;

NOW, THEREFORE, be it known to all whom it may concern:

THAT for good and valuable consideration the receipt of which is hereby acknowledged, ASF has and does hereby sell, assign, transfer and set over unto AMGEN, its successors and assigns, the full and exclusive right, title and interest including all rights acquired in foreign countries, in and to said Patents and Patent Applications (listed in Appendix A, attached hereto and incorporated herein by reference), including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, prolongations or extensions thereof, and in and to any and all letters patents to be granted and issued therefor, not only for, to and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said letters patents to AMGEN, in accordance with this assignment.

THIS 17<sup>th</sup> day of June 2005.

AMGEN SF, LLC.

By: Stuart L. Watt

Name: Stuart L. Watt

Title: Vice President,  
Law and Intellectual Property


STATE OF CALIFORNIA )

COUNTY OF VENTURA )

On 17 day of June 2005, before me personally appeared Stuart L. Watt, known to me to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.

L. Holtke  
Notary Public



# APPENDIX A

Amgen Docket No.	Law Firm Docket No.	Title	Serial No.	Filing Date
T99-002/US	018781-003300US	LXR Modulators	60/115,292	01/08/99
T99-002-1/US	018781-003310US	LXR Modulators	09/479,315	01/06/00
T99-002-1/PC	018781-003310PC	LXR Modulators	US00/03806	02/14/00
T99-005/US	018781-003000US	LXR Modulators	60/124,525	03/15/99
T99-015-1/US	018781-003610PC	CHANDRA: A TH1-Specific Gene	09/694,094	10/20/00
T99-015-1/PC	018781-003610PC	CHANDRA: A TH1-Specific Gene	US00/29253	10/23/00
T99-015-1-1/US	018781-003620US	CHANDRA: A TH1-Specific Gene	10/308,373	12/02/02
T99-018/US	018781-003900US	IRAK-4: Compositions and Methods of Use	60/176,395	01/13/00
T99-018-1/US	018781-003910US	IRAK-4: Compositions and Methods of Use	09/759,595	01/11/01
T99-018-1/PC	018781-003910PC	IRAK-4: Compositions & Methods of Use	US01/01171	01/12/01
T99-018-1/AU	018781-003910AU	IRAK-4: Compositions & Methods of Use	30926/01	01/12/01
T99-018-1/CA	018781-003910CA	IRAK-4: Compositions & Methods of Use	2,397,481	01/12/01
T99-018-1/EP	018781-003910EP	IRAK-4: Compositions & Methods of Use	01903060.0	01/12/01
T99-018-1/JP	018781-003910JP	IRAK-4: Compositions & Methods of Use	2001-551215	01/12/01
T99-018-2/US	018781-003920US	IRAK-4: Compositions and Methods of Use	10/990,276	11/14/04
T00-006/US	018781-005500US	Compounds for the Modulation of STAT6	60/246,876	11/08/01
T00-006-1/US	018781-005510US	STAT Modulators	10/008,244	11/07/01
T00-006-1/PC	018781-005510PC	STAT Modulators	US01/50760	11/08/01
T00-006-1-1/US	018781-005520US	STAT Modulators	11/014,344	12/14/04
T00-007/US	018781-005700US	Anti-inflammation Agents	60/243,581	10/26/00
T00-007-1/US	018781-005710US	Anti-inflammation Agents	10/004,287	10/23/01
T00-007-1/PC	018781-005710PC	Antiinflammation Agents	US01/51403	10/23/01
T00-007-1/AR	018781-005710AR	Antiinflammation Agents	P010105038	10/29/01
T00-007-1/AU	018781-005710AU	Antiinflammation Agents	2002239806	10/23/01
T00-007-1/BR	018781-005710BR	Antiinflammation Agents	0114978-4	10/23/01
T00-007-1/CA	018781-005710CA	Antiinflammation Agents	2427284	10/23/01
T00-007-1/CN	018781-005710CN	Antiinflammation Agents	01821344.8	10/23/01
T00-007-1/EA	018781-005710EA	Antiinflammation Agents	200300508	10/23/01
T00-007-1/EP	018781-005710EP	Antiinflammation Agents	01987605.1	10/23/01
T00-007-1/IL	018781-005710IL	Antiinflammation Agents	155519	10/23/01
T00-007-1/IN	018781-005710IN	Antiinflammation Agents	00657/DELNP	10/23/01
T00-007-1/JP	018781-005710JP	Antiinflammation Agents	2002-544024	10/23/01



# APPENDIX A

Amgen Docket No.	Law Firm Docket No.	Title	Serial No.	Filing Date
T00-007-1/KR	018781-005710KR	Antiinflammation Agents	2003-7005797	10/23/01
T00-007-1/MX	018781-005710MX	Antiinflammation Agents	PA/a/2003/003599	10/23/01
T00-007-1/NO	018781-005710NO	Antiinflammation Agents	20031869	10/23/01
T00-007-1/NZ	018781-005710NZ	Antiinflammation Agents	525474	10/23/01
T00-007-1/PH	018781-005710PH	Antiinflammation Agents	1-2003-500297	10/23/01
T00-007-1/PL	018781-005710PL	Antiinflammation Agents	P-366114	10/23/01
T00-007-1/SG	018781-005710SG	Antiinflammation Agents	200302309-0	10/23/01
T00-007-1/TW	018781-005710TW	Antiinflammation Agents	90126694	10/29/01
T00-007-1/ZA	018781-005710ZA	Antiinflammation Agents	2003/3203	10/23/01
T00-007-2/US	018781-005720US	Antiinflammation Agents	10/928,784	08/26/04
T00-009/US	018781-005900US	FXR Modulators	60/230,585	09/05/00
T00-009-1/US	018781-005910US	FXR Modulators	60/258,092	12/22/00
T00-009-2/US	018781-005920US	FXR Modulators	60/265,215	01/30/01
T00-009-3/US	018781-005930US	FXR Modulators	09/945,293	08/31/01
T00-009-3/PC	018781-005930PC	FXR Modulators	US01/27239	08/31/01
T00-009-4/US	018781-005940US	FXR Modulators	10/794,228	03/04/04
T00-010/US	018781-006000US	SSG Protein	60/198,465	04/18/00
T00-011/US	018781-006010US	Sitosterolemia Susceptibility Gene (SSG): Compositions & Methods of Use	60/204,234	05/15/00
T00-011-1/US	018781-006020US	Sitosterolemia Susceptibility Gene (SSG): Compositions & Methods of Use	09/837,992	04/18/01
T00-011-1/PC	018781-006020PC	Sitosterolemia Susceptibility Gene (SSG): Compositions & Methods of Use	US01/12758	04/18/01
T01-010/US	018781-009800US	CCR4 Antagonists	60/293,781	05/23/01
T01-010-1/US	018781-008600US	Modulation of CCR4 Function	09/975,566	10/11/01
T01-010-1/PC	018781-008600PC	Modulation of CCR4 Function	US01/42625	10/11/01
T01-010-1/CA	018781-008600CA	Modulation of CCR4 Function	2425259	10/11/01
T01-010-1/EP	018781-008600EP	Modulation of CCR4 Function	01981850.9	10/11/01
T01-010-1-1/US	018781-008610US	Modulation of CCR4 Function	10/654,112	09/02/03
T01-010-2/US	018781-009810US	CCR4 Antagonists	10/155,605	05/22/02
T01-010-2/PC	018781-009810PC	CCR4 Antagonists	US02/16393	05/22/02
T01-017/US	018781-010400US	Benzimidazole Derivatives	60/327,818	10/09/01
T01-017-1/US	018781-010410US	Benzimidazole Derivatives	10/268,412	10/09/02
T01-017-1/PC	018781-010410PC	Benzimidazole Derivatives	US02/32437	10/09/02
T01-017-1/AU	018781-010410AU	Benzimidazole Derivatives	2002332099	10/09/02

# APPENDIX A

Amgen Docket No.	Law Firm Docket No.	Title	Serial No.	Filing Date
T01-017-1/CA	018781-010410CA	Benzimidazole Derivatives	2458533	10/09/02
T01-017-1/EP	018781-010410EP	Benzimidazole Derivatives	02769042.9	10/09/02
T01-017-1/JP	018781-010410JP	Benzimidazole Derivatives	2003-533934	10/09/02
T01-022/US	018781-009600US	Inflammation Modulators	60/337,460	12/05/01
T01-022-1/US	018781-009610US	Inflammation Modulators	10/314,428	12/04/02
T01-022-1/AR	018781-00961AR	Inflammation Modulators	P020104697	12/04/02
T01-022-1/PC	018781-00961PC	Inflammation Modulators	US02/39134	12/04/02
T01-023/US	018781-008800US	Arylsulfonamidobenzyllic Compounds	60/353,497	01/30/02
T01-023-1/US	018781-008810US	Arylsulfonamidobenzyllic Compounds	10/354,922	01/29/03
T01-023-1/PC	018781-008810PC	Arylsulfonamidobenzyllic Compounds	US03/03149	01/29/03
T01-023-1/AU	018781-008810AU	Arylsulfonamidobenzyllic Compounds	2003210811	01/29/03
T01-023-1/CA	018781-008810CA	Arylsulfonamidobenzyllic Compounds	2,474,433	01/29/03
T01-023-1/EP	018781-008810EP	Arylsulfonamidobenzyllic Compounds	03735124.4	01/29/03
T01-023-1/JP	018781-008810JP	Arylsulfonamidobenzyllic Compounds	2003-563290	01/29/03
T01-026/US	018781-008900US	Heterocyclic Arylsulfonamidobenzyllic Compounds	60/353,496	01/30/02
T01-026-1/US	018781-008910US	Heterocyclic Arylsulfonamidobenzyllic Compounds	10/354,923	01/29/03
T01-026-1/PC	018781-008910PC	Heterocyclic Arylsulfonamidobenzyllic Compounds	US03/03148	01/29/03
T01-026-1/AU	018781-008910AU	Heterocyclic Arylsulfonamidobenzyllic Compounds	2003208952	01/29/03
T01-026-1/CA	018781-00891CA	Heterocyclic Arylsulfonamidobenzyllic Compounds	2,474,702	01/29/03
T01-026-1/EP	018781-008910EP	Heterocyclic Arylsulfonamidobenzyllic Compounds	03707677.5	01/29/03
T01-026-1/JP	018781-008910JP	Heterocyclic Arylsulfonamidobenzyllic Compounds	2003-563492	01/29/03
T02-008/US	018781-010000US	Anti-Inflammation Agents	60/412,300	09/20/02
T02-008-1/US	018781-010010US	Anti-Inflammation Agents	60/422,593	10/31/02
T02-008-2/US	018781-010020US	Anti-Inflammation Agents	60/422,531	10/31/02
T02-008-3/US	018781-010210US	Anti-Inflammation Agents	10/665,986	09/19/03
T02-008-4/US	018781-010110US	Anti-Inflammation Agents	10/666,857	09/19/03
T02-008-4/PC	018781-010110PC	Anti-Inflammation Agents	US03/29143	09/19/03
T02-008-4/AU	018781-010110AU	Anti-Inflammation Agents	2003270701	09/19/03
T02-008-4/CA	018781-010110CA	Anti-Inflammation Agents	To be provided	09/19/03
T02-008-4/EP	018781-010110EP	Anti-Inflammation Agents	03752410.5	09/19/03
T02-008-4/JP	018781-010110JP	Anti-Inflammation Agents	2004-549954	09/19/03
T03-013/US	018781-011400US	Asthma and Allergic Inflammation Modulators	60/485,978	07/09/03

## APPENDIX A

Amgen Docket No.	Law Firm Docket No.	Title	Serial No.	Filing Date
T03-013-1/US	018781-011410US	Asthma and Allergic Inflammation Modulators	10/887,341	07/07/04
T03-013-1/PC	018781-011410PC	Asthma and Allergic Inflammation Modulators	US04/21735	07/09/04

NOV. 28 2006 9:53AM

CHEMO CENTRYX

NO. 907 P. 2



**POWER OF ATTORNEY**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of Collins *et al.*

Confirmation No.: 4775

Serial No.: 10/654,112

Art Unit: 1626

Filed: September 2, 2003

Examiner: Ebenezer O. Sackey

For: MODULATION OF CCR4  
FUNCTION

Attorney Docket No.: 11134-065-999

**REVOCATION AND POWER OF ATTORNEY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**ChemoCentryx, Inc. (assignee) hereby revokes any and all previous powers and appoints:**

☒ Practitioners of Jones Day at Customer Number 20583

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

☒ The above mentioned Customer Number.

☒ Firm or Individual Name:

Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

ChemoCentryx, Inc. is the:


- ☐ Applicant/Inventor  
☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
*(Statement under 37 CFR 3.73(b) is applicable)*

SIGNATURE of Applicant or Assignee of Record			
Date:	11/29/06	Signature:	
		Typed Name:	Thomas J. Schall
		Position/Title:	President & CEO

NOV. 28. 2006 9:53AM

CHEMO CENTRYX

NO. 907 P. 3



**Statement Under 37 C.F.R. 3.73(b)**

ChemoCentryx, Inc. states that it is:

☒ the assignee of the entire right, title, and interest; or  
an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of:

- ☒ An assignment from the inventors Brian B. McMaster, Daniel J. Dairaghi and Thomas J. Schall of the patent application U.S. App. No. 09/975,566 filed October 11, 2001, from which the above-identified patent application is a divisional application. A copy of the assignment thereof is attached.
- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

**ASSIGNEE: ChemoCentryx, Inc.**

Date: 11/29/06

Signature: 

Typed Name: Thomas J. Schall

Position/Title: President & CEO

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

☒ Total of two forms are submitted.

Attorney Docket No.: 018781-008600US  
Client Reference No.: T01-010

**ASSIGNMENT OF PATENT APPLICATION**

**JOINT**

WHEREAS, Brian E. McMaster of 120 Walker Drive, Mountain View, CA 94043; Daniel J. Dairaghi of 2080 Cornell, Palo Alto, CA 94306; Thomas J. Schall of 530 Webster Place, #5, Palo Alto, CA 94301; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: MODULATION OF CCR4 FUNCTION

Date(s) of execution of Declaration: 03/20/02; 03/20/02; and 04/17/02

Filing Date: October 11, 2001

Application No.: 09/975,566


WHEREAS, ChemoCentryx, Inc. of 1539 Industrial Road, San Carlos, CA, 94070, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.


IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: 3/20/02


  
Daniel J. Dairaghi

SIGNATURE WITNESSED BY:

(1) Date: 3/20/02

  
Signature of Witness 1

(2) Date: 3/20/02

  
Signature of Witness 2

Dated: 3/20/02


  
Brian E. McMaster

SIGNATURE WITNESSED BY:

(1) Date: 3/20/02


  
Signature of Witness 1

(2) Date: 3/20/02

  
Signature of Witness 2


Assignment  
Attorney Docket No.: 018781-008600US  
Page 3

Dated: 4/16/02


  
Thomas J. Schall

SIGNATURE WITNESSED BY:

(1) Date: 4/16/02

  
Signature of Witness 1

(2) Date: 4/16/02

  
Signature of Witness 2